Pulse pressure, heart rate, and drug treatment of hypertension

Area of Science:

• Cardiovascular Medicine
• Hypertension Research
• Hemodynamics

Background:

• Systolic blood pressure (SBP) and diastolic blood pressure (DBP) are traditionally used to predict cardiovascular (CV) risk.
• Existing risk prediction models may not fully capture CV complications in both normotensive and hypertensive individuals.

Purpose of the Study:

• To highlight the importance of pulse pressure (PP) and heart rate (HR) as independent predictors of CV risk.
• To advocate for the inclusion of brachial PP and the PP x HR product in CV risk assessment.
• To emphasize the need for novel therapeutic strategies targeting arterial stiffness.

Main Methods:

• Review of existing literature on hemodynamic indices and cardiovascular outcomes.
• Analysis of the predictive power of PP and HR in normotensive and hypertensive populations.
• Evaluation of the impact of current antihypertensive therapies on SBP, DBP, and PP.

Main Results:

• Increased PP is a stronger independent predictor of myocardial infarction than SBP, even in hypertensive patients on medication.
• Elevated HR is an additional CV risk factor, particularly when combined with increased PP (PP x HR product).
• Standard antihypertensive drugs primarily reduce DBP, with less impact on SBP and PP.

Conclusions:

• Brachial PP and HR are critical hemodynamic factors for predicting coronary complications.
• Current antihypertensive treatments may be insufficient for optimal CV risk reduction due to limited effects on PP and arterial stiffness.
• Development of new drugs specifically targeting SBP, PP, and arterial stiffness is essential for improved CV event prevention.